Acute sensorineural hearing loss following intravenous ketoralac administration.
Ketoralac is an injectable nonsteroidal antiinflammatory drug (NSAID) widely used in both out-patient and in-patient settings. Side effects such as acute renal failure, hyperkalemia, gastritis, gastrointestinal bleeding, and asthmatic exacerbation, although rare, have been previously reported. We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac. The patient denied any previous medication sensitivities, and was taking oral methotrexate and prednisone at the time of emergency department admission. Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss. We postulate that the patient's hearing loss was the result of ketoralac's direct and indirect ototoxic effects that were potentiated as a result of her underlying illness and medications. We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID-induced ototoxicity could result in adverse otologic consequences.
Schaab
K C
KC
Albany Medical College, Department of Emergency Medicine, NY 12208, USA.
Dickinson
E T
ET
Setzen
G
G
D000208:Acute Disease; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001299:Audiometry; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007275:Injections, Intravenous; D020911:Ketorolac Tromethamine; D009443:Neuritis / Q000150:complications / Q000188:drug therapy; D010488:Polyarteritis Nodosa / Q000150:complications*; D014046:Tolmetin / Q000009:adverse effects / Q000031:analogs & derivatives*; D014325:Tromethamine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin